Verve's programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease. Read More >>
Whether you're developing a new oral solid dosage form or reformulating to meet evolving regulatory standards, this resource offers practical guidance grounded in real data.
Join us for a webcast on August 8th where SGS's Microbiology Manager, Patricia Peron, takes a deep dive into Bacterial Endotoxin Testing (BET), USP Chapter <86>. A case study and conclusions will be presented and followed by a Q&A session.
New joint venture will exclusively provide USP and EP-specific monograph testing for all frequently used gases in the drug and medical device development and manufacturing process.
This guide provides experienced insights for biopharmaceutical professionals who are interested in optimizing their development and manufacturing processes without compromising on quality.
Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle. We are trusted experts in R&D, diagnostic services, API manufacture, formulation development, clinical trial supply services and technologies through to commercial-scale manufacture and distribution.
Sentry BioPharma Services, Inc. (Sentry US) protects product SISPQ by offering compliant pharmaceutical services, including cGMP temperature-controlled storage, controlled substance management (CS III-V), clinical/commercial labeling and secondary packaging. Sentry also provides import/export optimization by leveraging our end-to-end GxP logistics, global distribution and Foreign Trade Zone expertise. Sentry’s status as a US Foreign Trade Zone enables products from outside the United States to be received and held within cGMP storage, pending approval for importation from the FDA, CBP and DEA. Sentry is VAWD accredited, licensed in all US states and inspected by the FDA, along with numerous international authorities. Sentry’s newest facility in Columbus, IN provides stock splitting risk mitigation services and will offer additional cGMP offerings in 2026.
